Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Nearly 70% of prior HBV vaccine nonresponders produced adequate antibodies after successful HCV treatment.
Hepatocellular carcinoma among people with HCV fell after the debut of direct-acting antivirals, but cases are rising for other groups.
However, researchers saw little difference across racial groups in HBV treatment initiation among those who were eligible.
Authors emphasize the need for increased hepatitis B vaccine awareness and education.
#NAIRHHADAY is now an officially recognized HIV awareness day. Join a September 14 webinar to learn why this matters.
While global hepatitis B virus prevalence has decreased, elimination by 2030 may not be feasible.
Generic drugs are cheaper and lead to better treatment compliance compared with brand-name drugs.
Hepatitis A and B declined in 2021, but new hepatitis C cases have doubled since 2014.
The American Red Cross started screening all donors using a questionnaire to evaluate behavior-based risk. Folks on PrEP may not donate.
In 2022, fatty liver disease accounted for nearly a quarter of all liver cancer cases on the transplant waiting list.
Researchers are working on a cure for hepatitis B and a vaccine and long-acting antivirals for hepatitis C.
About 40% of people worldwide are not aware that viral hepatitis is a leading cause of liver cancer.
Viral hepatitis could kill more people than malaria, tuberculosis and HIV combined if trends continue.
The proposal improves on current Medicare coverage, which allows cost-sharing fees and mostly excludes long-acting PrEP.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.